arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Veru Inc.

VERU Health Care Biotechnology: Pharmaceutical Preparations
$2.27
▼ -1.3% Today
as of Oct 23, 11:52 ET
Last 30 days -2.99% Sep 14 → Oct 23
$2.09 $2.24 $2.40 $2.55 $2.70 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$2.30
High
$2.30
Low
$2.24
Volume
$85,818
Avg Vol
$604,689
Mkt Cap
$44M
P/E (TTM)
—
Beta
—
52w High
$7.33
52w Low
$2.05
Div Yield
—
Shares Out
$17M

Recent Press Releases & News last 60 days · 2 items

Sep 8 · 12:17 PR GlobeNewswire
Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial
Sep 2 · 12:30 PR GlobeNewswire
Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference

VERU earnings at a glance

The options market is pricing a move of about ±15.6% after the report, a range of roughly $1.92 to $2.62 from today's $2.27. Over its last 2 reports the stock rose the next day 1 time and fell 1, moving ±2.2% on average; after the most recent report on May 13, 2026 it moved -0.4%. That means options currently expect more movement than VERU has typically delivered. VERU beat the consensus EPS estimate in 3 of its last 3 reported quarters. Implied volatility is currently 67%. The share price of $2.27 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$2.05
$7.33
4% of range
Avg surprise (last 3)
+30.2%
Avg reaction (last 2)
+1.8%
50% positive
Latest IV / EM
67%
EM ±15.6% · $3 · Oct 30

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.55$-0.43$-0.30$-0.18$-0.05 Actual $-0.42Actual $-0.08Actual $-0.07Actual $-0.05Est $-0.06Actual $-0.50Est $-0.55Actual $-0.13Est $-0.37 MarDecMarMar/2025Jun/2025Mar/2026
Revenue vs Net Income Revenue Net income
$-9M$-7M$-6M$-4M$-3M Dec 24Mar 25Jun 25Dec 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Wed May 13, 2026Mar/2026 $-0.13 $-0.37 +64.9% -160.0% -0.4% earnings
Tue Aug 12, 2025Jun/2025 $-0.50 $-0.55 +9.1% — — earnings
Thu May 8, 2025Mar/2025 $-0.05 $-0.06 +16.7% — +4.0% earnings
Sun Mar 31, 2024Mar 2024 $-0.07 — — — — financials
Sun Dec 31, 2023Dec 2023 $-0.08 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.42 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————$0$0——
Cost of revenue————————
Gross profit————————
Operating income$-8M$-7M$-5M—$-8M$-8M$-10M—
Net income$-7M$-3M$-5M—$-7M$-8M$-9M—
EPS (diluted)————————

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$24M$28M$33M$16M$15M$20M$27M$25M
Inventory————————
Total current assets$27M$33M$37M$19M$16M$21M$28M$35M
Total assets$37M$43M$48M$30M$27M$33M$40M$60M
Long-term debt————————
Total liabilities$9M$8M$10M$12M$12M$12M$13M$28M
Total equity$28M$35M$37M$18M$15M$21M$27M$32M

Implied volatility — last 90 days

67%250%434%617%801% Jun 07 — IV 291% · EM ±27.2%Jun 08 — IV 236% · EM ±19.7%Jun 09 — IV 244% · EM ±17.7%Jun 10 — IV 392% · EM ±23.2%Jun 15 — IV 210% · EM ±15.2%Jun 16 — IV 281% · EM ±16.6%Jun 17 — IV 430% · EM ±18.0%Jun 22 — IV 172% · EM ±14.4%Jun 23 — IV 184% · EM ±13.3%Jun 24 — IV 227% · EM ±13.4%Jun 29 — IV 156% · EM ±36.9%Jun 30 — IV 110% · EM ±25.6%Jul 06 — IV 170% · EM ±14.2%Jul 08 — IV 380% · EM ±22.5%Jul 09 — IV 538% · EM ±22.5%Jul 13 — IV 140% · EM ±11.7%Jul 14 — IV 239% · EM ±17.3%Jul 15 — IV 280% · EM ±16.5%Jul 16 — IV 351% · EM ±14.6%Jul 20 — IV 390% · EM ±32.6%Jul 21 — IV 310% · EM ±22.4%Jul 22 — IV 599% · EM ±35.4%Jul 23 — IV 570% · EM ±23.8%Jul 27 — IV 285% · EM ±23.8%Jul 30 — IV 485% · EM ±20.3%Aug 04 — IV 256% · EM ±33.8%Aug 05 — IV 274% · EM ±34.3%Aug 06 — IV 273% · EM ±32.2%Aug 07 — IV 252% · EM ±27.9%Aug 10 — IV 474% · EM ±39.6%Aug 11 — IV 356% · EM ±25.8%Aug 12 — IV 494% · EM ±29.2%Aug 13 — IV 399% · EM ±16.7%Aug 17 — IV 68% · EM ±5.7%Aug 18 — IV 213% · EM ±15.4%Aug 24 — IV 345% · EM ±28.8%Sep 14 — IV 409% · EM ±34.2%Sep 15 — IV 473% · EM ±34.2%Sep 16 — IV 511% · EM ±30.2%Sep 17 — IV 801% · EM ±33.5%Sep 21 — IV 221% · EM ±18.4%Sep 22 — IV 152% · EM ±11.0%Sep 23 — IV 311% · EM ±18.4%Sep 28 — IV 92% · EM ±21.8%Sep 29 — IV 67% · EM ±15.6%

Sector peers

HOWL
Werewolf Therapeutics, Inc.
$45M $1.02-0.5%
GRCE
Grace Therapeutics, Inc.
$43M $1.90-3.8%
EDSA
Edesa Biotech, Inc.
$46M $2.72-4.6%
FLNA
Filana Therapeutics, Inc.
$47M $0.64-2.4%
NSRX
Nasus Pharma Ltd.
$40M $3.51+14.7%
CRVO
CervoMed Inc.
$48M $2.27-3.0%

VERU earnings FAQ

What is VERU's expected move for earnings?

Options currently price a move of about ±15.6%, or $0.35 per share either way from $2.27.

How does VERU stock usually react to earnings?

Across the last 2 reports the average next-day move was ±2.2%, up 1 times and down 1 times.

What is VERU's implied volatility?

VERU's at-the-money implied volatility is about 67% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in